Human diseases may be modeled in animals to allow preclinical assessment of putative
new clinical interventions. Recent, highly publicized failures of large clinical trials called into …

Adaptive designs for clinical trials permit alterations to a study in response to accumulating
data in order to make trials more flexible, ethical, and efficient. These benefits are achieved …

Cerebral ischemia and reperfusion initiate cellular events in brain that lead to neurological
disability. Investigating these cellular events provides ample targets for developing new …

The COVID-19 pandemic has led to an unprecedented response in terms of clinical
research activity. An important part of this research has been focused on randomized …

Large randomised trials provide the most reliable evidence of effectiveness of new
treatments in clinical practice. However, the time and resources required to complete such …

Background In recent years, the popularity of multi-arm multi-stage, seamless adaptive, and
platform trials has increased. However, many design-related questions and questions …

Background Multi-arm designs provide an effective means of evaluating several treatments
within the same clinical trial. Given the large number of treatments now available for testing …

Although decades of intensive drug discovery efforts to treat neurodegenerative disorders
(NDs) have failed, around half a million patients in more than 2000 studies continue being …

One family of designs that can noticeably improve efficiency in later stages of drug
development are multi‐arm multi‐stage (MAMS) designs. They allow several arms to be …

Platform trials evaluate the efficacy of multiple treatments, allowing for late entry of the
experimental arms and enabling efficiency gains by sharing controls. The power of …